

## **Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic.**

### **The COVID-19 Pandemic Breast Cancer Consortium:**

Representatives from the American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Care Network (NCCN), the Commission on Cancer (CoC), and American College of Radiology (ACR).

Jill R. Dietz, MD<sup>1,2,6</sup>; Meena S. Moran, MD<sup>1,3,7</sup>; Steven J. Isakoff, MD, PhD<sup>3,8</sup>; Scott H. Kurtzman, MD<sup>1,9</sup>; Shawna C. Willey, MD<sup>2,10</sup>; Harold J. Burstein, MD, PhD<sup>3, 11</sup>; Richard J. Bleicher, MD<sup>1,12</sup>; Janice A. Lyons, MD<sup>3,6</sup>; Terry Sarantou, MD<sup>1,13</sup>; Paul L. Baron, MD<sup>1,2,14</sup>; Randy E. Stevens, MD<sup>1,15</sup>; Susan K. Boolbol, MD<sup>2,16</sup>; Benjamin O. Anderson, MD<sup>3,17</sup>; Lawrence N. Shulman, MD<sup>4, 18</sup>; William J. Gradishar, MD<sup>3,19</sup>; Debra L. Monticciolo, MD<sup>5,20</sup>; Donna M. Plecha, MD<sup>5,6</sup>; Heidi Nelson, MD<sup>1,4</sup>; Katharine A. Yao, MD<sup>1,21</sup>

<sup>1</sup>National Accreditation Program for Breast Centers, Chicago, IL

<sup>2</sup>American Society of Breast Surgeons, Columbia, MD

<sup>3</sup>National Comprehensive Cancer Network, Plymouth Meeting, PA

<sup>4</sup>Commission on Cancer, Chicago, IL

<sup>5</sup>American College of Radiology, Reston, VA

<sup>6</sup>University Hospital Cleveland Medical Center, Cleveland, OH

<sup>7</sup>Yale Medicine, New Haven, CT

<sup>8</sup>Massachusetts General Hospital Cancer Center, Boston, MA

<sup>9</sup>Waterbury Hospital, Waterbury, CT

<sup>10</sup>Inova Schar Cancer Institute, Fairfax, VA

<sup>11</sup>Dana Farber Cancer Institute, Boston, MA

<sup>12</sup>Fox Chase Cancer Center, Philadelphia, PA

<sup>13</sup>Carolinas Medical Center, Charlotte, NC

<sup>14</sup>Montefiore Medical Center, Bronx, New York

<sup>15</sup>White Plains Hospital, White Plains, NY

<sup>16</sup>Nuvance Hospital, Poughkeepsie, NY

<sup>17</sup>University of Washington, Seattle, WA

<sup>18</sup>University of Pennsylvania, Philadelphia, PA

<sup>19</sup>Northwestern Medicine, Chicago, IL

<sup>20</sup>Baylor Scott & White Healthcare-Central Texas

<sup>21</sup>NorthShore University HealthSystem, Evanston, IL

**Corresponding author:**

Jill R. Dietz, MD, FACS

ASBrS (President),

NAPBC (Vice chair, Standards and Accreditation Committee)

Associate Professor of Surgery, Case Western Reserve University School of Medicine

Director Breast Operations University Hospitals Seidman Cancer Center

Cleveland, Ohio

[Jill.Dietz@UHhospitals.org](mailto:Jill.Dietz@UHhospitals.org)

Word count: 2966 (without tables)

Abstract word count: 239

References: 57

**STRUCTURED ABSTRACT**

The COVID-19 pandemic presents clinicians a unique set of challenges in managing breast cancer (BC) patients. As hospital resources and staff become more limited during the COVID-19 pandemic, it becomes critically important to define which BC patients require more urgent care and which patients can wait for treatment until the pandemic is over. In this Special Communication, we use expert opinion of representatives from multiple cancer care organizations to categorize BC patients into priority levels (A, B, C) for urgency of care across all specialties. Additionally, we provide treatment recommendations for each of these patient scenarios. Priority A patients have conditions that are immediately life threatening or symptomatic requiring urgent treatment. Priority B patients have conditions that do not require immediate treatment but should start treatment before the pandemic is over. Priority C patients have conditions that can be safely deferred until the pandemic is over. The implementation of these recommendations for patient triage, which are based on the highest level available evidence, must be adapted to current availability of hospital resources and severity of the COVID-19 pandemic in each region of the country. Additionally, the risk of disease progression and worse outcomes for patients need to be weighed against the risk of patient and staff exposure to SARS CoV-2 (virus associated with the COVID-19 pandemic). Physicians should use these recommendations to prioritize care for their BC patients and adapt treatment recommendations to the local context at their hospital.

## **INTRODUCTION**

The COVID-19 pandemic poses unprecedented challenges for patients, clinicians and healthcare systems. Across every facet of medicine, clinicians are responding to the pandemic by modifying patient care to minimize exposure risk and preserve resources, and the management of patients with cancer poses unique challenges.<sup>1</sup> To provide preliminary guidance on the prioritization and treatment of breast cancer (BC) during this severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, we assembled representatives from the American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Care Network (NCCN), the Commission on Cancer (CoC) and the American College of Radiology (ACR) to formulate an Expert Opinion. The objective of this Special Communication is to prioritize patient scenarios by urgency of treatment by specialty and to make treatment recommendations based on these priorities within each specialty. Given the rapidly evolving nature of the COVID-19 pandemic, time constraints prohibited a formal consensus statement.

These recommendations relate specifically to BC patients not suspected to have COVID-19-related illness. We acknowledge that there are limited prospective experiences to guide these recommendations. Furthermore, these recommendations are driven by the common goal to preserve hospital resources for virus-inflicted patients by deferring BC treatments without significantly compromising long-term outcomes for individual BC patients. The demands that the COVID-19 pandemic will place on healthcare institutions remain unpredictable and will have geographical variability. Therefore, the risks of disease progression and compromised BC-specific outcomes need to be weighed against viral exposure to patients and staff, taking into consideration each individual's comorbidities and age to predict risk of mortality from COVID-

19. Lastly, these are recommendations and are not intended to supersede individual physician judgement or institutional policies and guidelines.

## **METHODS**

After extensive multidisciplinary teleconference discussions and literature review, a “Priority” classification for BC patients was developed across the disciplines. Priority categories were defined based on the severity of an individual patient’s condition (including patient co-morbidities) and potential efficacy of treatments.<sup>2</sup>

### ***Priority A Category:***

Priority A patients have a condition that is immediately life threatening, clinically unstable, or completely intolerable and for whom even a short delay would significantly alter the patient’s prognosis. Assuming efficacious treatment, these patients are given top priority even if resources become scarce, requiring urgent treatment for preservation of life or control of progressing disease or symptomatic relief.

### ***Priority B Category:***

Patients in the Priority B category are patients who do not have immediately life-threatening conditions but for whom treatment or services should not be indefinitely delayed until the end of the pandemic. Most BC patients will fall under Priority B. If conditions in a geographic location only allow for Priority A patients to receive treatment, then treatment for Priority B patients can be delayed for a defined period of time during the pandemic. A short delay (e.g. 6-12 weeks) would not impact overall outcome for these patients. Longer delays could impact outcomes in some Priority B patients and triage may become necessary to justify

which patients should undergo treatment versus further delay. Patients within the Priority B category will be sub-stratified as B1 (higher priority), B2 (mid-level priority) and B3 (lower priority) as defined by each BC subspecialty.

***Priority C Category:***

Patients in Priority C category are patients for whom certain treatment or services can be indefinitely deferred until the pandemic is over without adversely impacting outcomes.

**RESULTS**

Priority categories and treatment recommendations by specialty are listed below.

*Outpatient visits*

During the pandemic, the majority of encounters should be conducted remotely via telemedicine. Decisions to conduct in-person visits must carefully weigh the risk of viral transmission to patients and healthcare providers with the need for an in-person evaluation. Priority A includes, for example, clinically unstable post-operative patients and those with potential medical oncologic emergencies (e.g. febrile neutropenia, intractable pain) who need to be assessed in-person. Priority B patients should be evaluated by at least one member of the multidisciplinary team in-person or remotely depending on need. These include: newly diagnosed BC patients; established patients with new problems (breast infection, palpable findings, and significant symptoms from therapy); patients on active IV chemotherapy; patients completing neoadjuvant therapy preparing for surgery; routine postoperative patients; and patients being evaluated and planned for radiation therapy. Priority C patients are those

presenting for routine follow up for benign or malignant conditions (including those on oral adjuvant agents and those not on active treatment), survivorship visits, or high-risk screening and can be seen remotely or delayed until the post-pandemic period. Increased precautions should be taken surrounding in-person visits/treatments for patients with co-morbidities and a high risk of COVID-19 complications.

### *Breast Focused Imaging*

Few scenarios are designated Priority A for breast imaging, with the exception of imaging for urgent situations such as a severe breast abscess formation or for evaluation of a serious post-operative complication..

Breast imaging Priority B includes diagnostic imaging for an abnormal mammogram or for suspicious breast symptoms, biopsies for BI-RADS 4 or 5 lesions, and breast MRI for extent of disease evaluation or pre-chemotherapy assessment. Biopsies for lower suspicion lesions (BI-RADS 4a) may be postponed or biopsied. BIRADS category 3 patients returning for short-term follow-up diagnostic mammogram and/or ultrasound and routine breast exam should be postponed until the COVID-19 pandemic is over and would be Priority C. All screening exams including mammography, ultrasound, and MRI should be placed in Priority C and suspended until the post-COVID-19 period. BRCA mutation carriers under the age of 40 may be considered for screening if delays of more than 6 months are expected.<sup>3,4</sup>

### *Surgical Oncology*

**Table 1.** lists patient scenarios into Priority categories for urgency of surgical care. The need to minimize use of operating room resources requires selectively deferring surgery and

triaging patients for use of an initial alternative therapy whenever possible. However, level II evidence demonstrates that preoperative delays may impact BC outcomes.<sup>5,6</sup>

Invasive BC patients should be triaged with multidisciplinary input and assessment of patient's risks and co-morbidities to potentially receive neoadjuvant therapies during the pandemic. While neoadjuvant chemotherapy confers risks of immunosuppression and uses personal protective equipment (PPE), high risk breast cancers would fall in Priority B because upfront surgery is not required when systemic treatment is initiated. Current standards for triple negative breast cancer (TNBC) and human epidermal growth factor 2-overexpressing (HER2+) BC already include neoadjuvant therapy, which has very high rates of clinical and pathological tumor response affording durable tumor control prior to deferred surgery.<sup>7,8</sup>

Patients completing neoadjuvant chemotherapy are categorized as Priority B1. Delays of surgery up to 8 weeks post-chemotherapy do not adversely affect BC outcomes.<sup>9</sup> Breast imaging cannot be used as a surrogate to assess pathologic response because false negative rates vary between 17.8 and 50%.<sup>10-13</sup> In the event that resources do not allow for surgery, additional non-surgical therapy should be considered (see Medical Oncology section).

Patients with hormone receptor-positive BC are Priority B3 or C because neoadjuvant endocrine therapy allows for deferment of definitive surgery. Studies evaluating tamoxifen with/without surgery demonstrate no difference in survival within the first three years suggesting that short-term deferment of surgery with endocrine therapy should not adversely impact BC-specific survival.<sup>14-16</sup>

Patients eligible for breast conservation should be discouraged from elective mastectomy depending on local institutional resources. For patients requiring mastectomy, immediate



reconstruction with implant or tissue expanders can be performed only if hospital resources permit. Autologous reconstruction should be deferred.<sup>17</sup>

Discordant biopsies are uncommon, but when they occur, establishing the presence of malignancy is required.<sup>18</sup> These patients would be categorized in Priority B or C depending on level of suspicion.

For newly-diagnosed, recurrent BC, staging evaluation is preferred but may be unavailable. Surgery is typically indicated only in the absence of metastatic disease. Treatment will depend on resource availability (see Medical Oncology section).

Re-operation for margins or axillary staging is Priority C when there is a low likelihood of residual disease.<sup>19</sup> Patients with estrogen receptor positive (ER+) ductal carcinoma in situ (DCIS) and low volume ER- DCIS are Priority C1 whereas patients at high-risk for occult invasion are Priority B3. Non-operative trials however, are limited to low-risk DCIS.<sup>20-22</sup>

Practitioners caring for BC see many benign conditions. If a malignant lesion is unlikely, diagnostic procedures should be postponed. It is advisable to follow-up with patients whose treatment is being altered or postponed. The enormity of changes from the COVID-19 pandemic itself are anxiety-provoking among patients and practitioners. Patient psychological well-being needs to be considered and often can be addressed with telemedicine/phone visits. While shared decision-making is ideal, in the context of the pandemic difficult choices must be made.

*Medical Oncology*

**Table 2** lists patient scenarios into Priority categories for urgency of either hormonal, chemotherapy and/or targeted therapy. The medical oncology goals are to minimize patient interactions with healthcare centers, maintain patient safety, and conserve resources while providing effective care. All specialty and institutional goals and patient factors should be considered when formulating a treatment plan. Priority A patients are those with oncologic emergencies requiring immediate treatment (e.g. febrile neutropenia, intractable pain). Priority B patients require systemic care but are candidates for modified therapeutic approaches to achieve the goals above; the urgency and therapeutic options are stratified into higher-to-lower priorities (B1-B3). Priority C patients can delay interventions for many months without adverse impact on survival or quality of life.

### **Invasive BC – Early Stage**

For newly-diagnosed BC patients, multidisciplinary plans can be revised to protect patients and spare healthcare services (Priority B). Depending on local circumstances, surgery, systemic therapy, and radiation therapy (RT) sequencing may be altered to ensure patient safety and healthcare system needs. Neoadjuvant treatment is well established for all BC subtypes and enables delayed surgery. If necessary, RT can be given before adjuvant chemotherapy (especially for ER+ tumors) without affecting long term outcomes.<sup>23</sup>

Patients with ER+, HER2- tumors can defer surgery and receive neoadjuvant endocrine therapy for 6 to 12 months without clinical compromise (Priority B1).<sup>24,25</sup> Patients should be assessed periodically to confirm absence of tumor progression. Patients with Stage 1 or limited Stage 2 disease (including those with N1 nodal involvement), and those with low-intermediate grade tumors, lobular BCs, low-risk genomic assays (especially the recurrence score, which may be sent from a core biopsy<sup>26</sup>), or “luminal A” signatures, do not benefit substantially from

neoadjuvant or adjuvant chemotherapy<sup>27,28</sup>. These patients may receive endocrine therapy alone.

TNBC patients should receive standard chemotherapy approaches (Priority B1), and all BC subtypes currently receiving neoadjuvant or adjuvant treatment should complete standard regimens already underway. Abbreviated schedules or dose modified regimens may be considered. Single-agent sequential therapy may reduce treatment complications without compromising efficacy.<sup>29</sup>

Patients with Stage 1 or 2, HER2+ BCs may consider ado-trastuzumab emtansine (+/- pertuzumab) with comparable efficacy to chemotherapy/trastuzumab-based regimens in either neoadjuvant or adjuvant settings (Priority B2) to minimize neutropenia, visits, and steroid-use.<sup>30,31</sup> Adjuvant trastuzumab-based therapy may be shortened from 12 to 6 months without affecting outcomes in selected patients (Priority B3).<sup>32,33</sup>

### **Invasive BC – Advanced Stage**

Patients with advanced (metastatic) BC have many treatment options and typically receive multiple lines of therapy which are rarely dependent on specific treatment sequencing. Dose and schedule adjustments of systemic treatments are reasonable to reduce clinic visits, bloodwork, and development of significant side effects. Patients without signs or symptoms of tumor progression may defer routine restaging scans. When the likely benefit of additional palliative chemotherapy is very small, patients may find the risks of treatment outweigh the possible gains in outcome.

Trastuzumab, pertuzumab, and related antibody-drug conjugates for HER2+ tumors may be given at less frequent dosing intervals, as necessary. Patients with HER2+ BC with > 2 years

duration of tumor control and minimal disease burden with trastuzumab-based regimens may consider interrupting maintenance therapy.<sup>34</sup>

The use of oral targeted agents (CDK4/6, mTOR, and PIK3CA inhibitors) in ER+, metastatic BC must be weighed against the increased risk of adverse events. Dose reductions can minimize treatment-related toxicities. CDK4/6 inhibitors as first/second-line treatment offer clinical advantage, but may be delayed if the likelihood of tumor control is high with endocrine therapy alone (first line, no prior endocrine treatment, no visceral disease).<sup>35</sup> Dose reduction of palbociclib does not diminish efficacy.<sup>36,37</sup>

### **High Risk Lesions and Pre-Invasive BC**

High-risk lesions such as atypical hyperplasia and lobular carcinoma in-situ express ER and are effectively treated with either tamoxifen or aromatase inhibitors.<sup>38,39</sup> ER+ DCIS can be treated with preoperative endocrine therapy for 6 months (Priority C).<sup>40</sup> For management of ER-disease see Surgical Oncology section.

### **Supportive care and additional considerations**

Endocrine treatments (tamoxifen, aromatase inhibitors, luteinizing hormone releasing hormone (LHRH) agonist) are safe and can be continued thru the COVID-19 pandemic (**Table 3**). LHRH agonists may be given every 3 months, and home administration is an option.<sup>41</sup> Patients receiving chemotherapy should receive appropriate supportive care to reduce side effects; in particular, granulocyte colony-stimulating factor (G-CSF) should be used to minimize neutropenia, and can be considered for regimens with <20% chance of febrile neutropenia not usually offered G-CSF. Interventions that alleviate severe symptoms should remain a high priority. Bone modifying treatments (intravenous bisphosphonates or denosumab) can be

deferred in patients without hypercalcemia, on adjuvant therapy, or on long-standing courses of therapy.

### *Radiation Oncology*

Radiation therapy (RT) plays an integral role in the treatment of many BCs. Patient-related factors (age, comorbidities) contributing to infection risk must be carefully weighed against the risk of worsened BC outcomes if delaying the anticipated local-regional and potential survival benefits of RT. Priority A includes patients presenting with symptomatic disease in whom short palliative RT regimens should be utilized.<sup>42-44</sup> Patients clinically progressing on neoadjuvant therapy should be considered for a longer definitive pre-operative hypofractionated (HF) regimen to reduce risk of continued progression if surgically unresectable or resource constraints prohibit timely surgery.<sup>45,46</sup>

The majority of RT referrals will likely be Priority B requiring triage/deferment. Limited published data on RT delays in the definitive setting are inconsistent. Locally-advanced or inflammatory patients may have worse outcomes after neoadjuvant chemotherapy if RT is delayed >8 weeks (Priority B1).<sup>47</sup> In contrast, delaying RT 20 weeks in early-stage, ER+ patients after BCS demonstrates no difference in outcomes compared to 4-8 weeks (Priority B3).<sup>48</sup> Since Priority B sub-stratifies by clinical-pathologic recurrence risk, B1 patients should be given priority over B2 or B3; hypofractionated (HF) regimens should be strongly considered whenever possible. Long-term outcomes with HF-RT utilizing 42.5Gy/16 or 40 Gy/15 fractions demonstrate safety and efficacy similar to conventional fractionation which will reduce patient/staff exposure.<sup>45,46</sup> Though regional-nodal and post-mastectomy patients were under-represented in these trials, historic<sup>49</sup> and emerging<sup>50</sup> data suggest no differences in efficacy or toxicity for these sub-groups. Current trials are evaluating HF with reconstruction

(Alliance221505/ NCT03414970; FABREC Trial/ NCT03422003). Furthermore, additional intensive regimens after lumpectomy (FAST: 28.5 Gy in 5 once-weekly fractions<sup>51,52</sup>; FAST Forward: 26 Gy in 5 fractions over 1 week<sup>53</sup>) suggest early toxicity comparable to 40 Gy/15 fractions. These regimens may be considered in selected patients undergoing breast RT (without regional-nodal RT). Similarly, a boost should be reserved for patients with greatest absolute benefit (e.g. positive margins, age  $\leq 40$ ).<sup>54</sup>

Priority C patients are those in whom RT does not affect survival outcomes and includes all DCIS with exception of ER- DCIS with positive margins (Priority B3), if re-excision is not possible. Patients  $\geq 65$ -70 years with early-stage, node-negative, ER+ invasive disease should start endocrine therapy after surgery, with RT safely omitted or deferred until the pandemic is over.<sup>55,56</sup> A mechanism should be in place to re-evaluate patients for whom standard RT therapy is deferred so that recurrences/disease progression can be detected and managed appropriately.

## **DISCUSSION**

The three Priority levels we have defined reflect the urgency of treatment during this pandemic resulting in multidisciplinary management recommendations taking into account the burden of the COVID-19 pandemic on our health system.

### *Hospital Factors to Consider in Prioritization of BC Patients*

It is critical for physicians to understand the rapidly changing local conditions and available resources as well as risks/benefits of various treatments for patients, staff and hospital systems. Evolving local conditions and resources will influence which Priority category receives treatment. Factors to consider include supply and equipment inventory (ventilators, PPE) and availability of intensive care and inpatient beds. Other factors would be the proportion of healthcare personnel infected with SARS CoV-2, and whether BC treatment will put healthcare

workers at risk. Finally, the prevalence of regional community transmission will determine hospital capacity for outpatient care. These aforementioned factors will determine which BC patients receive treatment during or after the pandemic resolves.

#### *Importance of the Multidisciplinary Approach to the BC Patient*

The basic tenets of cancer care coordination should be followed as much as possible during the COVID-19 pandemic. Management of BC patients requires a highly integrated and multidisciplinary approach. An intervention in one specialty will have a direct impact on another specialty. For example, the American College of Surgeons issued a statement that elective surgeries should be canceled.<sup>17</sup> Fortunately, many BC patients do not need upfront surgical resection because of neoadjuvant treatment options. However, deferring BC cases will initially increase the medical oncologist workload and will result in a backlog of procedures when the pandemic resolves. For these reasons, multidisciplinary discussion documenting Priority category for surgery and/or adjuvant treatments is necessary to ensure the best outcomes for patients. If feasible, tumor board discussions should include both standard and COVID-19 recommendations based on institution's level of pandemic severity. Documentation of these discussions in the medical record is highly recommended.

#### *Future Directions*

This information should be used to organize a process of structured decision-making for the care of patients with breast disease during the COVID-19 pandemic. However, as the pandemic rapidly evolves, we are increasingly learning about viral transmission and its impact on the health system, thus, these recommendations will evolve over time with continued updates. This consortium will continue to adapt these recommendations to the current pandemic severity including future waves of the COVID-19 pandemic. It is our hope that these current

recommendations will help clinicians provide the highest quality care for their patients during this evolving pandemic.

#### **ACKNOWLEDGMENT**

There was no funding source.



## REFERENCES

1. Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2020:1-4.
2. Ontario Health. Pandemic Planning Clinical Guideline for Patients with Cancer. 2020. [https://www.accc-cancer.org/docs/documents/cancer-program-fundamentals/oh-cco-pandemic-planning-clinical-guideline\\_final\\_2020-03-10.pdf](https://www.accc-cancer.org/docs/documents/cancer-program-fundamentals/oh-cco-pandemic-planning-clinical-guideline_final_2020-03-10.pdf). Accessed 23 March 2020.
3. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. *Cancer*. 1998;83(11):2335-2345.
4. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. *Journal of the American College of Radiology : JACR*. 2018;15(3 Pt A):408-414.
5. Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to Surgery and Breast Cancer Survival in the United States. *JAMA Oncol*. 2016;2(3):330-339.
6. Ward WH, DeMora L, Handorf E, et al. Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer. *Annals of surgical oncology*. 2020;27(2):386-396.
7. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). *J Clin Oncol*. 2015;33(1):13-21.
8. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N Engl J Med*. 2019;380(7):617-628.
9. Sanford RA, Lei X, Barcenas CH, et al. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. *Annals of surgical oncology*. 2016;23(5):1515-1521.
10. Basik M, Cecchini RS, Santos JFDL, et al. Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. *Cancer Research*. 2020;80(4 Supplement):GS5-05-GS05-05.
11. Heil J, Pfob A, Sinn H-PP, et al. Abstract GS5-03: Diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: Results of a prospective multicenter trial. *Cancer Research*. 2020;80(4 Supplement):GS5-03-GS05-03.
12. Peeters M-JTFDV, van Loevezijn A, van der Noordaa ME, et al. Abstract GS5-06: Towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment). *Cancer Research*. 2020;80(4 Supplement):GS5-06-GS05-06.
13. Tasoulis MK, Lee H-B, Yang W, et al. Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A

- multi-institutional pooled analysis. *Cancer Research*. 2020;80(4 Supplement):GS5-04-GS05-04.
14. Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. *Br J Surg*. 2004;91(6):699-704.
  15. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. *Ann Oncol*. 2003;14(3):414-420.
  16. Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. *Anticancer Res*. 1994;14(5B):2197-2200.
  17. American College of Surgeons. COVID-19 Guidelines for Triage of Breast Cancer Patients. <https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer>. Published 2020. Accessed March 29, 2020.
  18. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. *JAMA*. 2004;292(22):2735-2742.
  19. Findlay-Shirras LJ, Outbih O, Muzyka CN, Galloway K, Hebbard PC, Nashed M. Predictors of Residual Disease After Breast Conservation Surgery. *Annals of surgical oncology*. 2018;25(7):1936-1942.
  20. Elshof LE, Tryfonidis K, Slaets L, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. *Eur J Cancer*. 2015;51(12):1497-1510.
  21. Francis A, Thomas J, Fallowfield L, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. *Eur J Cancer*. 2015;51(16):2296-2303.
  22. Youngwirth LM, Boughey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial. *Bull Am Coll Surg*. 2017;102(1):62-63.
  23. Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. *J Clin Oncol*. 2005;23(9):1934-1940.
  24. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2012;13(4):345-352.
  25. Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2016;2(11):1477-1486.
  26. Iwata H, Masuda N, Yamamoto Y, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. *Breast Cancer Res Treat*. 2019;173(1):123-133.
  27. Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. *Breast Cancer Res Treat*. 2017;165(3):573-583.
  28. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*. 2018;379(2):111-121.

29. Citron ML, Berry DA, Cirincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J Clin Oncol*. 2003;21(8):1431-1439.
30. Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. *J Clin Oncol*. 2019;37(25):2206-2216.
31. Tolaney SM, Trippa L, Barry W, et al. Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT). *Cancer Research*. 2020;80(4 Supplement):GS1-05-GS01-05.
32. Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. *Lancet*. 2019;393(10191):2599-2612.
33. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. *Lancet*. 2019;393(10191):2591-2598.
34. Moilanen T, Mustanoja S, Karihtala P, Koivunen JP. Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. *ESMO Open*. 2017;2(3):e000202.
35. Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. *Lancet*. 2020;395(10226):817-827.
36. Parulekar W, Joy A, Gelmon K, et al. Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693). *Cancer Research*. 2019;79(4 Supplement):PD1-10-PD11-10.
37. Zheng J, Yu Y, Durairaj C, et al. Abstract P5-21-21: Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). *Cancer Research*. 2018;78(4 Supplement):P5-21-21-P25-21-21.
38. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. *Lancet*. 2014;383(9922):1041-1048.
39. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst*. 1998;90(18):1371-1388.
40. Hwang ES, Hyslop T, Hendrix LH, et al. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). *J Clin Oncol*. 2020:JCO1900510.
41. Masuda N, Iwata H, Rai Y, et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. *Breast Cancer Res Treat*. 2011;126(2):443-451.

42. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst.* 2005;97(11):798-804.
43. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative Radiotherapy Trials for Bone Metastases: A Systematic Review. 2007;25(11):1423-1436.
44. Choi HS, Jang HS, Kang KM, Choi B-o. Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer. *Radiation Oncology.* 2019;14(1):110.
45. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *The Lancet Oncology.* 2013;14(11):1086-1094.
46. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med.* 2010;362(6):513-520.
47. Silva SB, Pereira AAL, Marta GN, et al. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. *Breast.* 2018;38:39-44.
48. Olivetto IA, Lesperance ML, Truong PT, et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. *J Clin Oncol.* 2009;27(1):16-23.
49. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. *N Engl J Med.* 1997;337(14):956-962.
50. Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. *Lancet Oncol.* 2019;20(3):352-360.
51. group FT, Agrawal RK, Alhasso A, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). *Radiother Oncol.* 2011;100(1):93-100.
52. Brunt AM. FAST Trial 10 year results *ASTRO 2018 Annual Meeting presentation slides* ASTRO 2018.
53. Brunt AM, Wheatley D, Yarnold J, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. *Radiotherapy and Oncology.* 2016;120(1):114-118.
54. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2009;27(30):4939-4947.
55. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. *Journal of Clinical Oncology.* 2013;31(19):2382-2387.

56. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *The Lancet Oncology*. 2015;16(3):266-273.
57. Gay HA, Santiago R, Gil B, et al. Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. *Pract Radiat Oncol*. 2019;9(5):305-321.

**Table 1. Priority Categories for Surgical Oncology**

<b>Priority</b>	<b>Patient Description</b>	<b>COVID-19 Treatment Considerations</b>
Priority A		
A	Breast abscess in a septic patient	Operative drainage if unable to be drained at the bedside
A	Expanding hematoma in a hemodynamically unstable patient	Operative evacuation and control of bleeding
Priority B		
B1	Ischemic autologous tissue flap	Revascularize or remove flap
B1	Revision of a full thickness ischemic mastectomy flap with exposed prosthesis	Debride and remove expander/implant
B1	Patients who have completed neoadjuvant chemotherapy for Inflammatory BC	Operate (mastectomy without reconstruction) as soon as possible depending on institutional resources
B1	TNBC and HER2 + patients	Neoadjuvant chemotherapy or HER2 targeted therapy. In some cases, institutions may decide to proceed with surgery first versus neoadjuvant therapy. These decisions will depend on institutional resources and patient factors.*
B2	Neoadjuvant: -finishing treatment -progressing on treatment	Operate if feasible depending on resources or extend/change neoadjuvant therapy*
B3	Clinical Stage T2 or N1 ER +/- HER2 - tumors	Consider hormonal treatment, delay operation
B3	Discordant biopsies likely to be malignant	Perform excisional biopsy when conditions allow
B3	Malignant or suspected local recurrence	Begin with staging when feasible. Perform excision when conditions allow if there is no distant disease.
Priority C		
C1	ER - DCIS	Delay operation until after COVID-19 unless there is a high risk of invasive cancer (Move to B3)
C1	Positive margin(s) for invasive cancer	Delay re-excision until after COVID-19
C1	Clinical Stage T1N0 ER +/- HER2 - cancers.	Hormonal treatment; delay operation until after COVID-19

C1	BC patients requiring additional axillary surgery	Delay operation until after COVID-19
C2	ER+ DCIS	Hormonal treatment; delay operation until after COVID-19
C2	High risk lesions	Delay operation until after COVID-19
C2	Reconstruction for previously completed mastectomy	Delay operation until after COVID-19
C3	Excision of benign lesions- fibroadenomas, nodules, papillomas, etc	Delay operation until after COVID-19
C3	Discordant biopsies likely to be benign	Delay operation until after COVID-19
C3	Prophylactic surgery-for cancer and noncancer	Delay operation until after COVID-19

\*Breast conservation is preferred provided that radiation oncology services are available, and the risk of multiple visits or deferred radiation is acceptable. If no ventilator is available or risk of viral exposure is high, breast conserving surgery could be performed under local with sedation. Reconstruction should be limited to tissue expander or implant placement if necessary, depending on institutional resources. Autologous reconstruction should be deferred.

BC, breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.

**Table 2. Priority Categories for Medical Oncology**

<b>Priority</b>	<b>Patient Description</b>	<b>COVID-19 Treatment Considerations</b>
Priority A		
A	Patients with oncologic emergencies (e.g. febrile neutropenia, hypercalcemia, intolerable pain, symptomatic pleural effusions or brain metastases, etc.)	Initiate necessary management
Priority B		
B1	Patients with inflammatory BC	Neoadjuvant chemotherapy
B1	Patients with TNBC or HER2+ BC	Neo/adjuvant chemotherapy (Neoadjuvant for $\geq T2$ or N1)
B1	Patients with mBC for whom therapy is likely to improve outcomes	Initiate chemotherapy, endocrine, or targeted therapy
B1	Patients who already started neo/adjuvant chemotherapy	Continue therapy until complete (if neoadjuvant and responding, can extend treatment if necessary to defer surgery further)
B1	Patients progressing on neoadjuvant therapy	Refer to surgery or change systemic therapy
B1	Patients on oral adjuvant endocrine therapy	Continue therapy
B1	Premenopausal patients with ER+ BC receiving LHRH agonists (adjuvant or metastatic)	- If on aromatase inhibitor, continue LHRH agonist and consider long acting 3 month dosing or home administration - If on tamoxifen, consider deferring LHRH agonist
B1	Patients with clinical anatomic Stage 1 or 2 ER+/HER2- BCs	Neoadjuvant endocrine therapy for 6 to 12 months to defer surgery (may consider gene expression assay on core biopsy)
B2	Patients receiving treatment for Stage 1 HER2+ breast	Ado-trastuzumab emtansine may be substituted for paclitaxel/ trastuzumab
B3	Patients with ER + DCIS	Consider neoadjuvant endocrine therapy to defer surgery
B3	Patients with mBC for whom therapy is unlikely to improve outcomes	Consider deferring chemotherapy, endocrine, or targeted therapy
B3	Patients with HER2+ mBC beyond 2 years of maintenance antibody therapy (trastuzumab,	Consider stopping antibody therapy with monitoring for progression every 3-6 months



	pertuzumab) with minimal disease burden.	
B3	Patients with HER2+ BC receiving adjuvant antibody treatment	Consider curtailing antibody treatment after 7 months instead of 12 months
Priority C		
C	Patients receiving zoledronic acid, denosumab	Discontinue bone antiresorptive therapy unless for hypercalcemia
C	Patients with stable mBC	Interval for routine follow up restaging studies can be delayed
C	Patients with lower risk imaging findings needing follow up (e.g. small pulmonary nodules)	Interval follow up can be delayed
C	Patients who are candidates for prevention measures (e.g. family history, LCIS or ADH, BRCA1/2+)	Consider endocrine therapy (as appropriate), delay surgery and screening imaging
C	Patients in long term follow up for early BC	Defer routine in-person visit
C	Patients on aromatase inhibitors	Defer bone density testing (baseline and follow up)

ADH, atypical ductal hyperplasia; BC, breast cancer; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LCIS, lobular carcinoma in situ; LHRH, luteinizing hormone releasing hormone; mBC, metastatic BC; TNBC, triple negative breast cancer.

**Table 3. Additional Considerations for Priority Categories for Medical Oncology**

<b>Agent</b>	<b>Dosing and Scheduling Considerations</b>
Chemotherapy	Chemotherapy schedules may be modified to reduce clinic visits (using 2- or 3-week dosing, e.g.) or to reduce infection risk (using weekly dosing) for selected agents when appropriate.
	For low risk febrile neutropenia, outpatient regimens may be used.
	Selected patients (particularly with ER+ disease), can consider radiation before chemotherapy if this facilitates patient safety.
Targeted Therapy	The addition of oral targeted agents (CDK 4/6, mTOR, or PIK3CA inhibitors) to endocrine therapy may be delayed in first-line treatment, or in situations where endocrine therapy alone is providing or is likely to provide effective tumor control.
	Cardiac monitoring (Echo, nuclear) during HER2 antibody therapy can be delayed or discontinued if clinically stable.
	Consider reduced dose of oral targeted agents to optimize tolerability and minimize treatment related toxicities.
	Trastuzumab and pertuzumab for metastatic HER2+ BC may reasonably be administered at longer intervals (e.g. 4 weeks).
Endocrine Therapy	Oral endocrine agents (e.g. tamoxifen, aromatase inhibitors) are not immunosuppressive and can be safely continued.
	Fulvestrant is not immunosuppressive but requires monthly clinical administration.
	Aromatase inhibitors are preferred over tamoxifen for neoadjuvant endocrine therapy (and LHRH agonists should be used for premenopausal women).
Supportive Care	Extend venous access device (port) flush to 12 weeks or longer
	Consider peripheral venous access for IV chemotherapy if patient has sufficient veins and no existing port if institutional policies permit.
	Administer G-CSF growth factor support to minimize neutropenia.
	Limit dexamethasone when possible to reduce immunosuppression.

BC, breast cancer; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; HER2, human epidermal growth factor receptor 2; IV, intravenous; LHRH, luteinizing hormone releasing hormone.

**Table 4. Priority Categories for Radiation Oncology**

<b>Priority</b>	<b>Patient Description</b>	<b>COVID-19 Treatment Considerations</b>
Priority A		
A	Bleeding/painful inoperable local-regional disease, Symptomatic metastatic disease	Consider palliative HF regimens
A	Progression of disease during NAC	Consider definitive HF regimens
Priority B		
B1	Inflammatory BC s/p mastectomy	Consider PMRT HF regimens
B1	Node positive: TNBC or HER2+ disease s/p BCT or mastectomy	Consider WBRT or PMRT HF regimens
B1	Post mastectomy with 4 or more tumor positive nodes	Consider PMRT HF regimens
B1	Residual node positive disease after NAC	Consider WBRT or PMRT regimens
B2	PMRT with 1-3 tumor positive nodes	Consider PMRT HF regimens
B2	Node negative: TNBC or HER2+ s/p BCT	Consider WBRT HF regimens
B2	If tumor positive margin after BCT for invasive BC with <u>no</u> alternative therapy options	Consider WBRT HF regimens
B3	If tumor positive margin after BCT for invasive BC <u>with</u> alternative therapy options	Consider WBRT HF regimens
B3	Young age ( $\leq 40$ years) s/p BCT, node negative with $\geq 1$ additional high-risk features (LVI+, PNI+)	Consider HF regimens
B3	ER- DCIS with a positive margin	Consider HF WBRT regimens
Priority C		
C	DCIS*	Initiate endocrine therapy if ER+ Defer radiation therapy until pandemic is over
C	>65 years early-stage, node-negative ER+/ HER2- taking	Omit radiation therapy or defer until pandemic is over

	adjuvant endocrine therapy s/p BCT	
<b>Hypofractionated Regimens:</b>		
Palliative Radiation		
4 Gy x 5 total 20 Gy		Meta-analysis <sup>43</sup>
8 Gy x 1 total 8 Gy		RTOG 97-14 <sup>42</sup>
<b>Whole breast radiation therapy:</b>		
2.67 Gy daily x 15 total 40.05 Gy		START B <sup>45</sup>
2.66 Gy daily x 16 total 42.56 Gy		Canadian <sup>46</sup>
5.7 Gy once per week x 5 total 28.5 Gy		FAST <sup>52</sup>
5.2-5.4 Gy daily x 5 total 26-27 Gy		FAST Forward <sup>53</sup>
<b>Post-mastectomy radiation therapy:</b>		
2.5 Gy daily x 15 to chest wall total 37.50 Gy; 2.5 Gy daily x 14 to regional nodes (including IMN) total 35 Gy		British Columbia PMRT trial <sup>49</sup>
2.90 Gy x 15 daily to chest wall, SC & Level III axilla total 43.5 Gy No IMN or reconstruction		China PMRT Trial <sup>50</sup>
2.66 Gy daily x 16 to chest wall + regional nodes (with IMN) total 42.56 Gy		NCT03414970
2.67 Gy daily x 15 to chest wall total 40.05 Gy, 2.67 x 14 to RNI total 37.38 Gy		NCT03422003
<b>Boost:</b>		
2.5 Gy x 4 total 10 Gy, consider additional 2.5 Gy fraction for positive margin		
<b>Considerations for treatment interruptions:</b>		
No change to WBRT, PMRT dose. Adjust boost as follows:		
No boost in original treatment plan: Add boost 2.5 Gy x 4		
Boost in original treatment plan: consider additional 2.5 Gy fraction to boost PTV total 12.5 Gy**		

BC, breast cancer; BCT, breast conserving therapy; ER, estrogen receptor; Gy; gray; HER2, human epidermal growth factor receptor 2; HF, hypofractionated; IMN, internal mammary node; LVI, lymphovascular invasion; NAC, neoadjuvant chemotherapy; PTV, planning tumor volume; PMRT, postmastectomy radiation therapy; PNI, peri-neural invasion; RNI, regional nodal irradiation; SC, supraclavicular; TNBC, triple negative breast cancer; WBRT, whole breast radiation therapy.

\*Exception to DCIS in Priority C is ER-negative DCIS with positive margin

\*\*Adapted from Gay HA, et al.<sup>57</sup>